Oppenheimer Reiterates Bullish View on Pieris Pharmaceuticals (PIRS) Following CRI Presentation
- Unemployment Rate Drops to 4.6%
- Unusual 11 Mid-Day Movers 12/2: (ASNA) (HTBX) (REPH) Higher; (PLX) (MEMP) (DRYS) Lower
- Bond yields fall on U.S. jobs data, euro flat before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and $10 price target on Pieris Pharmaceuticals (NASDAQ: PIRS) after the company presented a poster on its wholly-owned bispecific anticalin/mAb fusion protein PRS-343 (HER2xCD137), demonstrating in vivo efficacy compared to HER2 and CD137 (4-1BB) monocloanal antibodies. Pieris anticipates to initiate Phase 1 PRS-343 (HER2xCD137) in 1H17.
Gilson commented, "The presentation at CRI highlighted (1) the flexibility of the anticalin bispecific platform, (2) tumor localized increase in human TIL in vivo, (3) selectivity in T cell activation, leading to decreased peripheral T cell activation vs. 4-1BB mAb, and decreased mortality. We believe Pieris's approach may be differentiated in its safety and efficacy, as the HER2 mAb (trastuzumab) enhances efficacy with its anti-HER2 ADCC mechanism, while targeting CD137 engagement to the tumor microenvironmet."
Shares of Pieris Pharmaceuticals closed at $1.68 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Galena Biopharma (GALE) PT Raised to $4 at Maxim Group into San Antonio Breast Cancer Symposium
- BTIG Cuts PT on Workday (WDAY) to $88 Following Q3 Results; Affirms at 'Buy'
- Oppenheimer Cuts Price Target on Workday (WDAY) Following 3Q; Reiterates Outperform
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!